A decade of oncology drug development: FDA-approved drug trends between 2005 and 2015

被引：0
|
作者：
Asabere, Akwasi [1 ]
Bastian, Alex [1 ]
机构：
[1] GfK Market Access, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e17788
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17788
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The FDA-approved drug sofosbuvir inhibits Zika virus infection
    Bullard-Feibelman, Kristen M.
    Govero, Jennifer
    Zhu, Zhe
    Salazar, Vanessa
    Veselinovic, Milena
    Diamond, Michael S.
    Geiss, Brian J.
    ANTIVIRAL RESEARCH, 2017, 137 : 134 - 140
  • [22] A Zebrafish Drug Screen Repositions FDA-Approved Compounds for Radiochemotherapy
    Liu, P. H.
    Closser, E.
    Shah, R.
    Sidi, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S806 - S806
  • [23] Sources of drug information: FDA-approved labeling and other official FDA sources
    Lindstrom, Jill A.
    DERMATOLOGIC THERAPY, 2009, 22 (03) : 246 - 256
  • [24] Pharmacogenomic Biomarker Information in FDA-approved Paediatric Drug Labels
    Kim, Therasa
    Han, Nayoung
    Sohn, Minji
    Oh, Jung Mi
    Lee, Eui-Kyung
    Ji, Eunhee
    Kim, In-Wha
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 116 (05) : 438 - 444
  • [25] The First FDA-Approved Oral Drug for Multiple Sclerosis: Fingolimod
    Akman-Demir, Gulen
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 64 - 66
  • [26] Repurposing the FDA-approved drug carbidopa to treat human cancers
    Ganapathy, Vadivel
    Babu, Ellappan
    Ramachandran, Sabarish
    Bhutia, Yangzom D.
    CANCER RESEARCH, 2016, 76
  • [27] Repurposing an FDA-Approved Drug to Inhibit Bacterial Protein Toxins
    Borho, J.
    Eckert, A.
    Koegel, M.
    Barth, H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S32 - S32
  • [28] Scientific journey to the first FDA-approved drug for eosinophilic esophagitis
    Rothenberg, Marc E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (06) : 1325 - 1332
  • [29] Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
    Lin, Hui-Heng
    Zhang, Le-Le
    Yan, Ru
    Lu, Jin-Jian
    Hu, Yuanjia
    SCIENTIFIC REPORTS, 2017, 7
  • [30] Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels
    Conrado, Daniela J.
    Rogers, Hobart L.
    Zineh, Issam
    Pacanowski, Michael A.
    PHARMACOGENOMICS, 2013, 14 (02) : 215 - 223
12345